Integra LifeSciences
IART
186 hedge funds and large institutions have $1.82B invested in Integra LifeSciences in 2015 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 63 increasing their positions, 69 reducing their positions, and 15 closing their positions.
1,070% more call options, than puts
Call options by funds: $971K | Put options by funds: $83K
120% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 15
11% more funds holding
Funds holding: 168 → 186 (+18)
7% more capital invested
Capital invested by funds: $1.7B → $1.82B (+$123M)
9% less repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 69
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$13.8M |
| 2 |
Millennium Management
New York
|
+$12.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.6M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$8.61M |
| 5 |
SCM
Snow Capital Management
Sewickley,
Pennsylvania
|
+$5.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$41.7M |
| 2 |
O
OppenheimerFunds
New York
|
-$21.5M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$15.8M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$13M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$7.44M |
IART Hedge Fund Activity: Q2 2015 in Review
186 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q2 2015, worth a combined $1.82B — up 7.3% from $1.7B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new IART positions and 15 closed out — a net gain of 18 holders — while 63 added to existing stakes and 69 trimmed.
The largest buyer was HealthCor Management, adding an estimated $13.8M. The largest seller was Goldman Sachs, cutting an estimated $41.7M.
- 186 institutional investors held Integra LifeSciences (IART) as of Q2 2015, up from 168 in Q1 2015.
- Funds reported $1.82B of Integra LifeSciences stock for Q2 2015, up 7.3% quarter-over-quarter.
- 33 funds opened new Integra LifeSciences positions in Q2 2015 and 15 closed out, a net change of +18 holders.
- The largest Integra LifeSciences buyer in Q2 2015 was HealthCor Management, an estimated $13.8M added.
- The largest Integra LifeSciences seller in Q2 2015 was Goldman Sachs, an estimated $41.7M sold.
Based on aggregated 13F filings for Q2 2015.